New research found “that administering therapeutic dose anticoagulation with heparins reduced mortality, need for invasive mechanical ventilation (IMV) and thromboembolic events compared with prophylactic dose heparins.”
The research reviewed data from 18 clinical trials where patients received different doses of anticoagulants. According to a release from American College of Physicians, “The researchers found that administering therapeutic vs prophylactic-dose anticoagulation to patients hospitalized for COVID-19 was associated with 23% lower 28-day mortality. Mortality was higher for therapeutic vs intermediate dose anticoagulation; however, the researchers note that this comparison was not estimated precisely. Mortality risk was similar for similar for intermediate vs prophylactic dose anticoagulation. Risk of progression to IMV or death was similar to mortality risk. Across all dosage comparisons, the risk for major bleeding was higher, but the risk for thromboembolic events was lower.”
The study was published in Annals of Internal Medicine.
